Understand what drives HTA decisions.Shape what comes next.
Agorva™ combines AI-enabled technology with Remap’s market access expertise to turn complex HTA evidence into clear, actionable insight.
Book a demoAbout Agorva™
Agorva™ is Remap’s AI-enabled HTA intelligence platform, designed to help teams turn complex, fragmented evidence into clear, actionable insight.
Market access, pricing and HEOR teams often face three recurring challenges when reviewing HTA evidence:
- HTA and reimbursement evidence is fragmented across countries, agencies and source types
- Documents are often lengthy, published in different languages and structured inconsistently
- Headline outcomes rarely explain the restrictions, uncertainty and rationale behind a decision
Agorva™ is designed to make that process faster, clearer and more useful.
Agorva™ brings together HTA and reimbursement decisions from official agency sources and uses AI-enabled extraction, guided by a framework developed by Remap’s market access experts, to structure the detail behind each decision. Every insight can be traced back to the supporting source evidence, giving users greater transparency and confidence in the outputs.
Why Agorva™?
Plan ahead
Built for the JCA era of European access.
Compare PICO and evidence requirements across countries, understand how European assessments translate into national decisions, and build a clearer view of where local differences still matter.
Verify insights
AI-powered HTA intelligence you can trust.
Trace outputs back to source evidence, understand the basis for each insight, and move faster with AI-supported analysis without sacrificing transparency or confidence.
Decode decisions
Don’t just track HTA outcomes. Understand what drives them.
Go beyond headline outcomes to understand the factors driving HTA decisions, with key insights structured in English while preserving each HTA body’s assessment framework for clearer, more consistent comparison across countries.
Shape strategy
Design tomorrow’s evidence strategy with today’s HTA precedent.
Learn from relevant analogues, anticipate evidence needs and access risks early, and apply HTA precedent while there is still time to strengthen evidence generation, launch, pricing and portfolio strategy.
Comparing Agorva™ to other solutions
| Capability | Agorva™ | General-purpose AI assistants | Traditional HTA databases |
|---|---|---|---|
| Purpose-built for market access | Designed specifically for market access, pricing and HTA workflows | Designed for broad, cross-domain use | Built to record and track HTA outcomes, largely through manual data entry |
| Structured HTA analysis | Extracts and organises key decision drivers such as populations, endpoints, comparators, uncertainty and access conditions, curated from the full report rather than copied from a single section | Typically returns narrative responses that depend on the prompt; nuance such as restrictions and uncertainty may be missed unless asked for | Mostly headline outcomes; the rationale is often missing, or copied at length from the report without being digested, so the user still has to work through it |
| Cross-country comparison | Supports systematic comparison of decisions, rationales and evidence requirements across countries | Comparisons usually require repeated prompting and manual synthesis | Outcomes can be compared, but comparing rationale and evidence requirements usually means going back to the reports |
View full comparison
| Capability | Agorva™ | General-purpose AI assistants | Traditional HTA databases |
|---|---|---|---|
| Consistent decision analysis | Applies a consistent structure across HTA decisions and countries | Outputs can vary by prompt, user and conversation | Fixed fields give consistency, but categories are limited, and manual entry means style and depth vary between reviewers and editors |
| Persistent, reusable insight | Builds a structured repository of precedent and trend insight that can be revisited and reused, and filtered by product, country, population, endpoint, comparator and outcome | Often centred on individual conversations or one-off outputs, with limited filtering | Persistent records with standard search, but limited to the fields captured |
| Source traceability | Every insight links back to the exact supporting passage in the original source document | Source referencing and traceability can vary by tool and response | Usually link to the full source document, not to the supporting passage |
| Strategic application | Every data field is targeted and action-driven, so users can read it and immediately see what it means for evidence planning, launch, pricing and access strategy | Requires the user to interpret and translate outputs into strategy | Records that still need substantial reading and reasoning before they can inform strategy |
Agorva™ FAQs
What is Agorva™?
Agorva™ is Remap’s proprietary AI-enabled HTA intelligence platform, designed to help teams turn complex, fragmented evidence into clear, actionable insight. It brings together scientific, HTA and reimbursement evidence so teams can understand what is driving decisions across countries, compare precedent and apply those insights to future evidence, launch and access strategy.
Who is Agorva™ intended for?
Agorva™ is designed for market access, pricing and HEOR professionals working with complex HTA and reimbursement evidence. It is particularly relevant for global and regional teams involved in evidence planning, HTA strategy, launch preparation, pricing and reimbursement, portfolio assessment and JCA readiness.
How is Agorva™ different from general-purpose AI assistants and other HTA intelligence solutions?
Agorva™ is purpose-built for market access, pricing and HTA workflows rather than broad, cross-domain use. It combines structured analysis, source traceability and consistent cross-country comparison, while going beyond headline outcomes to help teams understand the populations, comparators, endpoints, restrictions, uncertainty and other factors driving each decision.
For a more detailed comparison, see Agorva™ versus general-purpose AI assistants and traditional HTA databases above.
Which countries are currently covered within Agorva™?
Agorva™ currently covers a defined set of priority European HTA markets, including England through NICE, Germany through G-BA, France through HAS and Spain through AEMPS, alongside relevant EMA regulatory information. Coverage will continue to expand as additional agencies and countries are incorporated into the platform.
Can insights within Agorva™ be traced back to the source evidence?
Yes. Insights within Agorva™ can be traced back to the underlying source evidence, allowing users to review the supporting material behind each output. This helps teams validate findings, understand the basis for the insight and use AI-supported analysis with greater confidence.
How is Agorva™ licensed?
Agorva™ is available through flexible licensing options designed to suit different team sizes and needs, including individual, team and enterprise access. Licensing can be tailored according to the number of users and intended use, and the Remap team can help identify the most appropriate option for your organisation.
How can I find out if Agorva™ is right for me and my organisation?
The Remap team can help you assess your current priorities and explore whether Agorva™ is the right fit for your team and organisation. Book a personalised demo today to see how the platform could support your specific needs.
What are early users of Agorva™ saying?
Pause quotesResume quotes
Understand what drives HTA decisions.Shape what comes next.
See how Agorva™ can help your team move from complexity to confident action.
Agorva™ is a trademark of Remap Consulting UK Ltd. Agorva™ uses AI to support analysis; outputs are linked to their source documents and should be reviewed by qualified professionals before being used to inform decision-making.